Université de Montréal
- Country
- 🇨🇦Canada
- Ownership
- -
- Established
- 1878-01-01
- Employees
- 4.9K
- Market Cap
- -
- Website
- https://www.umontreal.ca/
Clinical Trials
94
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (83 trials with phase data)• Click on a phase to view related trials
Pilot and Feasibility Study of Impact of SDF 38% Application on Oral Health of Elderly With Autonomy Loss
- Conditions
- Dental CariesElderlyLoss of AutonomySilver Diamine Fluoride
- Interventions
- Drug: placebo solution
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Université de Montréal
- Target Recruit Count
- 60
- Registration Number
- NCT07194629
- Locations
- 🇨🇦
Université de Montréal, Montreal, Quebec, Canada
🇨🇦Institut universitaire de gériatrie de Montreal, Montreal, Quebec, Canada
🇨🇦CHSLD Alfred Desrochers, Montreal, Quebec, Canada
Spotting and Managing Adult Repeated Traumas in the Brain
- Conditions
- Brain Injury Traumatic Mild
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Université de Montréal
- Target Recruit Count
- 200
- Registration Number
- NCT07025317
- Locations
- 🇨🇦
Christie Lab, Victoria, British Columbia, Canada
🇨🇦Jodie Gawryluk, Victoria, British Columbia, Canada
🇨🇦Faubert Lab, Montreal, Quebec, Canada
Comparison of Two Reeducation Methods in Children With Persistent Sleep Apnea, a Randomized Controlled Trial
- Conditions
- Obstructive Sleep Apnea of ChildSleep-Disordered BreathingAdenotonsillar Hypertrophy
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Université de Montréal
- Target Recruit Count
- 60
- Registration Number
- NCT06634264
- Locations
- 🇨🇦
CHU Sainte Justine, Université de Montréal, Montréal, Quebec, Canada
Effect of Defocus in Soft Contact Lenses on Internal Retinal Vascularization
- Conditions
- Nearsightedness
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Université de Montréal
- Target Recruit Count
- 25
- Registration Number
- NCT06527274
- Locations
- 🇨🇦
Universite de Montreal, Montreal, Quebec, Canada
Response and Remission to Treatment With Anti-IL5/IL5R Antagonists
- Conditions
- Asthma
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Université de Montréal
- Target Recruit Count
- 109
- Registration Number
- NCT06348173
- Locations
- 🇨🇦
Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 19
- Next
News
Epitopea's CryptoMap Platform Identifies Novel Immunotherapy Targets in Melanoma and NSCLC
Epitopea's CryptoMap platform identified 589 non-redundant tumor antigens in cutaneous melanoma and NSCLC, with only 1% derived from mutated sequences.
Gut Microbiome Emerges as Key Player in Cancer Immunotherapy Response, New Research Shows
Recent research reveals specific bacterial networks in the gut microbiome can predict cancer patients' response to immunotherapy, with Akkermansia muciniphila and Faecalibacterium prausnitzii identified as beneficial species.